Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying filgotinib as a potential treatment for children and adolescents aged 8 to under 18 years with moderately to severely active ulcerative colitis UC. This Phase 3 study aims to evaluate how well filgotinib works, its safety, tolerability, and how the body processes the drug in this younger population. Approximately 80 participants will be enrolled, including at least eight children aged 8 to under 12 years. Participants will take filgotinib tablets once daily in the morning, with or without food, using age-appropriate doses targeting similar blood levels as adults treated with 200 mg daily. The drug will be taken at home on most days, but on-site dosing will occur at Weeks 4, 10, and 22. Those who do not reach remission or response by Week 10 will continue induction treatment until Week 22. Participants not achieving remission by Week 22 will stop the study treatment. Throughout the study, researchers will assess the drugs effectiveness in inducing remission at Week 10 and maintaining it up to Week 58. Safety and tolerability will also be monitored up to Week 62. Participants will be evaluated regularly with clinical assessments, and adherence will be supported by on-site dosing visits. The total study duration extends to about 58 to 62 weeks, ensuring thorough monitoring of treatment outcomes and participant health.
Actively Recruiting
Researchers are evaluating whether baricitinib can delay the onset of clinical type 1 diabetes T1D in children and adults who are at high risk of developing this condition. This Phase 3, double-blind, randomized, placebo-controlled study includes participants aged 1 to less than 36 years with early-stage type 1 diabetes or specific diabetes-related autoantibodies. The study is sponsored by Eli Lilly and Company and aims to understand if baricitinib can postpone progression to stage 3 T1D. Participants will be randomly assigned to receive either baricitinib or a placebo orally. The intervention period may last up to approximately 5 years, during which the time from baseline to diagnosis of stage 3 type 1 diabetes will be closely monitored. Both groups will be followed to assess changes in glucose metabolism, C-peptide levels, body measurements, and quality of life. During the study, participants will undergo regular assessments including blood tests to measure glucose-stimulated C-peptide, glucose levels, and other metabolic markers at baseline and after one year. Additional evaluations include body height, body mass index percentile, and health surveys. Pharmacokinetics of baricitinib will also be monitored up to week 24. Safety and efficacy data will be collected throughout the study period, lasting up to approximately 5 years per participant.
Actively Recruiting
Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Corabotase also called IPN10200 for treating adults with upper limb spasticity. This study aims to understand how Corabotase affects the body and to determine which doses provide the best balance of safety and benefit. The trial involves adult participants aged 18 to 70 years who have spastic hemiparesis following stroke or traumatic brain injury and meet other specific health criteria. The study includes several groups receiving different doses of Corabotase, Dysport, or placebo as single injections into various upper limb muscles. Participants are assigned randomly to groups, with some in dose-escalation cohorts and others in fixed-dose groups. The injections are given once, and doses are carefully adjusted to assess safety and response. The trial uses a double-blind design, meaning neither participants nor researchers know who receives which treatment. Participants will be monitored over nine months with regular assessments including physical exams, vital signs, lab tests, and evaluations of muscle spasticity using the Modified Ashworth Scale. Researchers will track any side effects, antibody development, and changes in muscle tone and disability. Patient and physician impressions of treatment effects and pain levels will also be recorded. This long-term follow-up helps researchers understand how the treatments work and their safety over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the Hydrustent4 biodegradable hydrogel ureteral stent in adults with urinary lithiasis who have undergone surgery to remove ureteral or renal stones. The study will compare Hydrustent4 to a standard ureteral stent device to determine if it is at least as safe and effective in maintaining urine flow through the ureter after surgery. The trial includes both a pilot phase to explore initial safety and efficacy and a pivotal phase to confirm clinical performance. Participants will receive either the Hydrustent4 stent or a comparator ureteral stent after stone removal surgery. The Hydrustent4 device is designed to degrade naturally in the body, potentially avoiding the need for a second surgery to remove the stent, while the comparator is a conventional polyurethane double loop stent. The study will monitor the durability of the device for at least 24 hours and assess whether the device reduces urinary symptoms and prevents additional surgical procedures. During the 3-month follow-up period, participants will attend regular visits for assessments including questionnaires, imaging exams, and blood and urine tests to monitor recovery and device performance. Researchers will closely track safety through adverse events and device issues, evaluate urine drainage after stent placement, and assess symptoms related to the stents. The study will measure both technical success and tolerability of the devices throughout the treatment and follow-up phases.
Actively Recruiting
Crohns disease is a long-lasting condition causing severe inflammation in the digestive tract, mainly affecting the bowels. Symptoms include belly pain, diarrhea, tiredness, and weight loss. This study evaluates targeted therapies for adults with moderate to severe Crohns disease, aiming to understand their effectiveness and side effects. The trial is a Phase 2a randomized platform study involving about 590 participants worldwide. Participants will be randomly assigned to receive one of several treatments risankizumab, trosunilimab, lutikizumab, or ABBV-8736, administered either by injection under the skin or infusion into the vein. Some groups receive combination therapies involving different doses and delivery methods. A long-term extension allows risankizumab monotherapy for up to 72 weeks. Treatments are given at hospitals or clinics in scheduled visits. During the study, participants attend regular visits for medical assessments including blood tests, endoscopies, and questionnaires. Researchers monitor treatment effects, side effects, and disease activity using tools like endoscopic remission and clinical remission scores. Safety and adverse events are tracked up to approximately 96 weeks. Participants keep daily diaries and complete questionnaires to aid data collection.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.